Sort   by:  
 Page size 
Thalidomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective treatments of hematologic malignancies. It was shown that IMiDs impart gain of function properties to the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) ubiquitin ligase that enable binding, ubiquitination and degradation of key the...
ORGANISM(S): Homo sapiens (Human) 
2017-05-29 | PXD005857 | Pride
Thalidomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective treatments of hematologic malignancies. It was shown that IMiDs impart gain of function properties to the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) ubiquitin ligase that enable binding, ubiquitination and degradation of key the...
ORGANISM(S): Homo sapiens (Human) 
2017-05-29 | PXD005849 | Pride
ZFP91 and IKZF1 Cooperatively Promote IMiD Resistance in T-Cell Lymphomas
The immunomodulatory (IMiD) agents, such as lenalidomide, are highly effective treatment for several B cell lymphomas but have poor efficacy in T cell lymphomas (TCLs). Here, we show that IKZF1 is a key drug target and vulnerability in lenalidomide sensitive TCL cells. However, TCLs are largely resi...
ORGANISM(S): Homo sapiens 
2022-04-21 | GSE172505 | GEO
Thalidomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective treatments of hematologic malignancies. It was shown that IMiDs impart gain of function properties to the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) ubiquitin ligase that enable binding, ubiquitination and degradation of key the...
ORGANISM(S): Homo sapiens 
2017-03-01 | GSE94728 | GEO
Sort   by:  
 Page size